All Drug Targets articles – Page 15
-
ArticleCould illuminating the surfaceome help find new targeted cancer therapies?
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface ...
-
NewsOvercoming chemotherapy resistance in pancreatic cancer
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
-
ArticleHow MMR-deficient colorectal cancers regulate their growth
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
-
NewsDeveloping a globally-applicable HIV cure
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
-
NewsStudying the epigenetic profile of beta cells in insulinoma
Researchers found that tumour beta cells lose their repression marks and express elevated levels of oncogenes.
-
NewsElucidating the loss of mobility caused by LGMD2B
The hiPSC-derived skeletal muscle model is the first to uncover the biological mechanisms underlying loss of mobility.
-
NewsThe potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
-
NewsMini-colons offer improved cellular diversity, longevity and function
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
-
WebinarThe value of GPCR cell-based assays in drug discovery
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
-
NewsNew 3D genomic profiling technique details PanINs
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
-
NewsNew ENaC blocker demonstrates an extended duration of action
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
-
NewsWerner syndrome: mechanism behind atherosclerosis elucidated
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
-
NewsP. aeruginosa infection method elucidated with microtissue model
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
-
ArticleA T cell receptor immunotherapy against a novel target
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
-
NewsNew biological pathway in IBD discovered
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
-
NewsMitigating fibrotic barriers in pancreatic cancer
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
-
NewsProteogenomics: finding targets for never-smoker lung cancer
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
-
NewsTargeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
-
NewsThe therapeutic potential of targeting guidance receptors
Researchers found that relaxing glial spacing by targeting Plexin-B1 has great therapeutic potential for Alzheimer’s disease.
-
ArticleLeveraging ADCs in precision oncology strategy
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.